PinPoint Testing, LLC Consulting

Drug Detection

The recent challenge of identifying synthetic cannabinoids (“K2” and “Spice”), designer stimulants (“bath salts”), opioids, and other illicit compounds in blood and urine specimens has burdened toxicology laboratories as well as the judicial system.

The effects of synthetic cannabinoids can be unpredictable and severe or even life-threatening; but their use continues to rise.

In 2010, DEA reported that 30–35% of specimens submitted by juvenile probation departments tested positive for synthetic cannabinoids, and according to the 2011 National Institutes of Drug Abuse (NIDA)-sponsored Monitoring the Future survey, 11% of high school seniors reported smoking synthetic marijuana in the past year, making it one of the most commonly abused drugs in this population—second only to marijuana. Furthermore, researchers recently reported that 4.5% of urine specimens collected from 5,956 U.S. athletes tested positive for synthetic cannabinoids, the highest of all drug classes detected (1).

In addition to the synthetic cannabinoids, other stimulants , hallucinogens, and fentanyl-based opioids continue to appear as illicit drug makers constantly change the structure of these “designer” drugs to evade detection in most testing platforms. PinPoint Testing, LLC is the industry expert on synthetic drug detection and is continually updating our knowledge to provide the broadest and most relevant consulting to help detect and quantify these rapidly moving targets.

PinPoint Testing, LLC has helped laboratories plan and develop methods on thousands of drugs including opiates, opioids (including fentanyl analogs) benzodiazepine, stimulants, cannabinoids, synthetic designer drugs. Contact us today to learn how we can work with your laboratory or assist with judicial service’s needs.